Navigation Links
QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
Date:9/24/2009

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 24 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and Pink Sheets: QRXPY), announced today a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market. The strategic alliance involves Nuokang investing US$5.0 million for a controlling interest in a Hong Kong company that holds a license over two of QRxPharma's lead haemostasis product candidates: Textilinin, an antifibrinolytic agent, and Haempatch(TM), a potent pro-coagulant.

The transaction is expected to be completed by mid October 2009. On completion, a minority interest in the Hong Kong company will be held by Venomics Pty Ltd, which is a majority-owned subsidiary of QRxPharma and holds all of the venomics assets of QRxPharma. An affiliated company of Nuokang has also subscribed to a 10% interest in Venomics Pty Limited.

"We are very pleased to announce the strategic alliance of QRxPharma's venomics program with a leading Chinese biopharmaceutical company that has extensive experience in the development, manufacture and sale of therapeutics derived from snake venoms," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Blood loss in surgery and trauma is a significantly under-served market opportunity, and Nuokang's capabilities and resources will ensure that Textilinin and Haempatch(TM) progress quickly to the clinic."

Dr. Holaday further said that he was particularly pleased to have concluded this deal:

"This strategic alliance provides a great opportunity to extract value for QRxPharma shareholders from the venomics assets without diverting management's attention away from QRxPharma's main prospect with its Dual Opioid(TM) development programme in the area of pain management".

Venomics Pty Limited will be led by Ms. Janette Dixon as CEO and Dr. John Holaday as Chairman of the Board of Directors. Ms. Dixon has extensive experience in the pharmaceutical and biotech sectors and spent a large part of her career working in Asia. Before joining QRxPharma in 2008, Ms. Dixon was the Managing Director of Pacific Pharmaceuticals Ltd, one of New Zealand's largest pharmaceutical manufacturing companies. "The Hong Kong entity holds the license to commercialise Textilinin and Haempatch(TM) in China. Data generated through the development of these products in China will support partnering activities in other territories. The Nuokang partnership minimizes the development costs for Textilinin and Haempatch(TM) while maximizing future potential returns to QRxPharma," said Ms. Dixon.

Nuokang is a leading, fully integrated China-based biopharmaceutical company focused on haematological and cardiovascular products. Nuokang's flagship product, Baquting, is one of China's most widely used haemocoagulase products for the treatment or prevention of bleeding. Baquting contains an enzyme obtained from the venom of the snake species Bothrops atrox.

Textilinin is a novel recombinant peptide that inhibits plasmin, a key enzyme in the fibrinolytic pathway and has potential to reduce blood loss in major surgery. In pre-clinical testing, Textilinin has compared favourably to other antifibrinolytic products such as Trasylol(R) (aprotinin), a product used to reduce perioperative blood loss in patients undergoing coronary artery bypass graft surgery (CABG). Trasylol(R) enjoyed peak annual sales in excess of US$300 million before it was withdrawn from many markets due to concerns over its side effect profile.

Haempatch(TM) is a novel prothrombin activating protease, with properties similar to the human Factor Xa clotting factor. It is highly effective in clotting blood and stopping blood flow (haemostasis) and has compared favourably to thrombin in pre-clinical testing. Both Haempatch(TM) and the native form of Textilinin were originally isolated from the venom of the Australian Common Brown snake (Pseudonaja textilis) by researchers at The University of Queensland (UQ). A collaborative R&D project has been ongoing since 2003 between QRxPharma and this UQ research team to further develop Textilinin and Haempatch(TM) and screen Australian snake venoms for therapeutic leads. A jointly owned pipeline of early stage candidates has been developed.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and Pink Sheets: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo(TM) IR, the first combination opioid product for the improved control of moderate to severe pain, successfully completed a Phase 3 study and a pilot Combination Rule study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: www.QRxPharma.com.


'/>"/>
SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President
2. QRxPharma Begins Trading on the International OTCQX
3. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
4. I-Therapeutix, Inc. Announces Company Name Change
5. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
7. US Farms, Inc. Announces Broker Network Agreement With Sunshine Specialties for Aloe365 Products
8. ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
9. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
10. Strategic Information Group Announces QAD Enterprise Validation Partnership
11. Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... BrightStar Care Marietta announced that it has received ... Pulse. This award is granted only to top-ranking home care providers, based on client ... ranked among home care providers from across the country who have proven their ability ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Much attention ... concern for women who become dependent on opioid painkillers has fallen short. From 1999 ... compared to a 237% increase in fatal overdoses in male populations.(1) , The proportion ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... Vancouver, BC (PRWEB) , ... February 27, 2017 ... ... top drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at ... (RMT) to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... FRANCISCO , February 28, 2017 The global  pulse ... a new report by Grand View Research, Inc. The pulse oximeters market is ... to the growing prevalence of target diseases such as chronic obstructive pulmonary disease ... Continue Reading ... Grand View Research ...
(Date:2/28/2017)... , Feb 28, 2017 Nordic Nanovector ASA (OSE: ... 2016. A presentation of the results by the company,s senior management ... Oslo - details below. ... 2016 was a very successful year for ... development of Betalutin®, progressed with our preclinical candidates and build the ...
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
Breaking Medicine Technology: